The trajectory of the erectile dysfunction drug presents a complex picture for investors. While the initial launch generated significant gains, the end of its patent opened the door to cheaper competitors, dramatically https://expressbookmark.com/story21629448/the-copyright-and-the-pharmaceutical-industry-a-precarious-investment